W Wiktor-Jędrzejczak

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text

Medicine, Hematology, Pharmacology +17

Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse.

W Wiktor-Jędrzejczak, A. Bartocci, Anthony W. Ferrante et al. · Proceedings of the National Academy of Sciences · 1990 · 1K citations · Full text

Medicine, Immunology, Bone Metabolism +9

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 788 citations

Medicine, Pharmacology, Pharmacotherapy +15

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Antonio Palumbo, Roman Hájek, Michel Delforge et al. · New England Journal of Medicine · 2012 · 739 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Michael Wang, Kristie A. Blum, Peter Martin et al. · Blood · 2015 · 402 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10